Methylphenidate for prison inmates with ADHD: yes or no?
The British Journal of Psychiatry · 2023
DOI: 10.1192/bjp.2022.139 ↗Kurz gefasst
Editorial in der Zeitschrift The British Journal of Psychiatry, 2023. Verfasst von Samuele Cortese. Beteiligte Einrichtung: School of Psychology, Centre for Innovation in Mental Health (CIMH), Faculty of Environmental and Life Sciences, University of Southampton, UK; Solen…. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Methylphenidate, Prisoners. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
In a double-blind randomised controlled trial by Asherson et al., involving prisoners with attention-deficit hyperactivity disorder (ADHD), the rates of response to osmotic-release oral system methylphenidate (OROS-methylphenidate) and placebo were very similar (~50%). I critically discuss this trial against other international literature, highlighting the key issues in the field in terms of clinical practice and research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Psychology, Centre for Innovation in Mental Health (CIMH), Faculty of Environmental and Life Sciences, University of Southampton, UK; Solent NHS Trust, Southampton, UK; Hassenfeld Children's Hospital at NYU La…
ORCID-Profile: Samuele Cortese
Zitieren
APA
Cortese, S. (2023). Methylphenidate for prison inmates with ADHD: yes or no?. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.2022.139
Vancouver
Cortese S. Methylphenidate for prison inmates with ADHD: yes or no?. The British Journal of Psychiatry. 2023. doi:10.1192/bjp.2022.139
BibTeX
@article{Cortese2023,
author = {Cortese, Samuele},
title = {Methylphenidate for prison inmates with ADHD: yes or no?},
journal = {The British Journal of Psychiatry},
year = {2023},
doi = {10.1192/bjp.2022.139}
}
EUVIMED